02:01 PM EDT, 05/07/2024 (MT Newswires) -- ImmunityBio ( IBRX ) shares rose almost 10% in recent trading after the company shared the completion and qualification Tuesday of the drug substance for filling vials and finishing packaging enough for 170,000 doses of 400mcg Anktiva.

The completion of the drug substance manufacturing will help provide the company with a "significant initial supply" of Anktiva, an immunotherapy for non-muscle invasive bladder cancer in combination with BCG, for commercial and clinical trial use.

Price: 8.57, Change: +0.76, Percent Change: +9.71